B cells enhance early innate immune responses during bacterial sepsis
The Journal of Experimental Medicine 208(8): 1673-1682
Article 2011 English
Authors
KK
Kindra M. Kelly‐Scumpia
PS
Philip O. Scumpia
JW
Jason S. Weinstein
Abstract
1 min read
Microbes activate pattern recognition receptors to initiate adaptive immunity. T cells affect early innate inflammatory responses to viral infection, but both activation and suppression have been demonstrated. We identify a novel role for B cells in the early innate immune response during bacterial sepsis. We demonstrate that Rag1−/− mice display deficient early inflammatory responses and reduced survival during sepsis. Interestingly, B cell–deficient or anti-CD20 B cell–depleted mice, but not α/β T cell–deficient mice, display decreased inflammatory cytokine and chemokine production and reduced survival after sepsis. Both treatment of B cell–deficient mice with serum from wild-type (WT) mice and repletion of Rag1−/− mice with B cells improves sepsis survival, suggesting antibody-independent and antibody-dependent roles for B cells in the outcome to sepsis. During sepsis, marginal zone and follicular B cells are activated through type I interferon (IFN-I) receptor (IFN-α/β receptor [IFNAR]), and repleting Rag1−/− mice with WT, but not IFNAR−/−, B cells improves IFN-I–dependent and –independent early cytokine responses. Repleting B cell–deficient mice with the IFN-I–dependent chemokine, CXCL10 was also sufficient to improve sepsis survival. This study identifies a novel role for IFN-I–activated B cells in protective early innate immune responses during bacterial sepsis.
Judit Kiss, Martin Mollenhauer, Sarah R. Walmsley, Johanna Kirchberg, Praveen Radhakrishnan, Thomas Niemietz, Johanna Dudda, Gunnar Steinert, Moira K. B. Whyte, Peter Carmeliet, Massimiliano Mazzone, Jürgen Weitz, Martin Schneider
Laure Janot, Jean‐Claude Sirard, Thomas Sécher, Nicolas Noulin, Lizette Fick, Akira Shizuo, Satoshi Uematsu, Arnaud M. Didierlaurent, Tracy Hussell, Bernhard Ryffel, François Erard
Discussion(0)
No comments yet. Be the first to comment.